These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12324632)

  • 1. Update on the treatment of cervical and uterine carcinoma: focus on topotecan.
    Fiorica JV
    Oncologist; 2002; 7 Suppl 5():36-45. PubMed ID: 12324632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of topotecan in the treatment of advanced cervical cancer.
    Fiorica JV
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S16-21. PubMed ID: 13129491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan in cervical cancer.
    Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
    Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
    Herzog TJ
    Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for recurrent cervical cancer.
    Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
    Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
    Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
    Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
    Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
    Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
    Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
    Kunos C; Deng W; Dawson D; Lea JS; Zanotti KM; Gray HJ; Bender DP; Guaglianone PP; Carter JS; Moore KN
    Int J Gynecol Cancer; 2015 Mar; 25(3):484-92. PubMed ID: 25594147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
    Traina TA; Sabbatini P; Aghajanian C; Dupont J
    Gynecol Oncol; 2004 Oct; 95(1):235-41. PubMed ID: 15385138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for endometrial cancer: experience with topotecan.
    Holloway RW
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S28-33. PubMed ID: 13129493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan in the treatment of gynecologic cancer.
    Coleman RL; Miller DS
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.
    Tewari KS; Monk BJ
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):108-15. PubMed ID: 20386532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase-I inhibitors in gynaecologic tumours.
    Verschraegen CF; Kudelka AP; Kavanagh JJ
    Ann Acad Med Singap; 1998 Sep; 27(5):683-7. PubMed ID: 9919340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
    Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
    Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical treatment of metastatic or recurrent cancer of the cervix].
    de la Motte Rouge T; Pautier P; Hamy AS; Duvillard P; Bruna A; Castaigne D; Morice P; Haie-Meder C; Lhommé C
    Bull Cancer; 2006 Mar; 93(3):263-70. PubMed ID: 16567313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.